A 510(k), formally a premarket notification under section 510(k) of the Food, Drug, and Cosmetic Act, is the pathway most Class II medical devices take to market in the United States. Instead of proving safety and effectiveness from scratch, you demonstrate that your device is substantially equivalent to a legally marketed device (a “predicate”).
When you need a 510(k)
Most Class II devices require a 510(k) before they can be marketed. Some Class I and a few Class II devices are exempt, and novel low-to-moderate-risk devices with no predicate may use the De Novo pathway instead. The first question to answer is therefore: does a suitable predicate exist?
What “substantial equivalence” actually means
A device is substantially equivalent when it has the same intended use as the predicate and either the same technological characteristics, or different characteristics that do not raise new questions of safety and effectiveness and are supported by performance data. Getting the predicate and the equivalence argument right is the single most important part of the submission.
The core sections FDA expects
A complete 510(k) generally includes:
- Device description and intended use / indications for use
- Substantial-equivalence discussion and a side-by-side predicate comparison
- Proposed labeling (including the instructions for use)
- Performance testing: bench, biocompatibility, electrical safety (IEC 60601), software (IEC 62304), sterilization, and any clinical data if required
- Risk management consistent with ISO 14971
As of FDA’s transition, most 510(k)s must now be submitted through the eSTAR electronic template, which enforces completeness before FDA will accept the submission.
Timeline and what slows it down
FDA’s review goal is roughly 90 FDA days, but the clock pauses during an Additional Information (AI) request, and a submission can be bounced early under the Refuse to Accept (RTA) policy if it is incomplete. The most common causes of delay are a weak predicate choice, gaps in performance testing, and inconsistent intended-use language across the submission and labeling.
Common pitfalls
- Choosing a predicate that does not truly match the intended use
- Underestimating testing (especially software, biocompatibility, and cybersecurity documentation)
- Labeling that claims more than the testing supports
- Treating risk management as a checkbox rather than an integrated process
Authoring a 510(k) is as much regulatory strategy as it is paperwork. I have authored and submitted 510(k)s to the FDA, including the GentleBeam clearance (K250692). If you are planning a submission, Sequence Group can build the strategy, write the submission, and manage it through clearance, get in touch.